Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study

Kim A. Papp; R. G. Langley; B. Sigurgeirsson; M. Abe; D. R. Baker; P. Konno; S. Haemmerle; H. J. Thurston; C. Papavassilis; H. B. Richards

doi:10.1111/bjd.12110

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study

Kim A. Papp, R. G. Langley, B. Sigurgeirsson, M. Abe, D. R. Baker, P. Konno, S. Haemmerle, H. J. Thurston, C. Papavassilis, H. B. Richards

Inernational Relations Division

Research output: Contribution to journal › Article › peer-review

327 Citations (Scopus)

Original language	English
Pages (from-to)	412-421
Number of pages	10
Journal	British Journal of Dermatology
Volume	168
Issue number	2
DOIs	https://doi.org/10.1111/bjd.12110
Publication status	Published - Feb 2013

ASJC Scopus Subject Areas

Dermatology

Access to Document

10.1111/bjd.12110

Cite this

Papp, K. A., Langley, R. G., Sigurgeirsson, B., Abe, M., Baker, D. R., Konno, P., Haemmerle, S., Thurston, H. J., Papavassilis, C., & Richards, H. B. (2013). Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study. British Journal of Dermatology, 168(2), 412-421. https://doi.org/10.1111/bjd.12110

Papp, KA, Langley, RG, Sigurgeirsson, B, Abe, M, Baker, DR, Konno, P, Haemmerle, S, Thurston, HJ, Papavassilis, C & Richards, HB 2013, 'Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study', British Journal of Dermatology, vol. 168, no. 2, pp. 412-421. https://doi.org/10.1111/bjd.12110

@article{d5256f21becd4bd089eb0b76b995e4d4,

title = "Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study",

author = "Papp, {Kim A.} and Langley, {R. G.} and B. Sigurgeirsson and M. Abe and Baker, {D. R.} and P. Konno and S. Haemmerle and Thurston, {H. J.} and C. Papavassilis and Richards, {H. B.}",

year = "2013",

month = feb,

doi = "10.1111/bjd.12110",

language = "English",

volume = "168",

pages = "412--421",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis

T2 - A randomized, double-blind, placebo-controlled phase II dose-ranging study

AU - Papp, Kim A.

AU - Langley, R. G.

AU - Sigurgeirsson, B.

AU - Abe, M.

AU - Baker, D. R.

AU - Konno, P.

AU - Haemmerle, S.

AU - Thurston, H. J.

AU - Papavassilis, C.

AU - Richards, H. B.

PY - 2013/2

Y1 - 2013/2

UR - http://www.scopus.com/inward/record.url?scp=84873124241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873124241&partnerID=8YFLogxK

U2 - 10.1111/bjd.12110

DO - 10.1111/bjd.12110

M3 - Article

C2 - 23106107

AN - SCOPUS:84873124241

SN - 0007-0963

VL - 168

SP - 412

EP - 421

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 2

ER -

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this